2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/0fma7nlq6immz.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/1chr5wkk3j58k.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T78a7,

Summary Table

Category	Details
Risk Factors	Children under 5 in developing countries, severe malnutrition (kwashiorkor/marasmus), fat malabsorption (cystic fibrosis, celiac disease, cholestatic liver disease, chronic pancreatitis), recent measles infection, post-bariatric surgery, chronic alcoholism, exclusive rice-based diets
Etiology	Vitamin A (retinol) deficiency causing impaired epithelial differentiation and reduced rhodopsin synthesis
Patient Presentation	Difficulty seeing at dusk or in dim light (earliest complaint), dry gritty eyes, photophobia, inability to produce tears when crying, frequent respiratory or diarrheal infections
Classic Physical Exam	Bitot's spots (foamy triangular grayish-white patches on bulbar conjunctiva, usually temporal), conjunctival and corneal xerosis, keratomalacia (corneal softening), follicular hyperkeratosis on skin
Key Diagnostic Results	Serum retinol $< 20\ \mu g/dL$ ($< 0.70\ \mu mol/L$), abnormal dark adaptation test, abnormal electroretinography, low retinol-binding protein
Management	High-dose oral vitamin A on day 1, day 2, and day 15 (dosing by age); treat underlying cause; manage corneal complications urgently
Keywords	"Cannot see at dusk," "night blindness," "Bitot's spots," "foamy white triangular patches," "malnourished child after measles," "rice-only diet," "cystic fibrosis with dry eyes"

1. Pathophysiology

Vitamin A (retinol) is a fat-soluble vitamin with two roles in ocular health: maintaining epithelial integrity through mucin-producing goblet cells and serving as the substrate for rhodopsin synthesis in rod photoreceptors. When you understand these two roles, the entire clinical picture writes itself.

In the retina, retinol is converted to 11-cis-retinal, which combines with opsin to form rhodopsin, the visual pigment responsible for vision in low-light conditions. When vitamin A drops, rhodopsin cannot be regenerated quickly enough after light exposure, and the rods fail first. This is why nyctalopia (night blindness) is always the earliest symptom; cones, which handle daytime and color vision, are spared until very late.

In the conjunctiva and cornea, vitamin A drives the differentiation of mucin-secreting goblet cells. Without it, these cells disappear and the surface epithelium undergoes squamous metaplasia with keratinization. The conjunctiva loses its glistening moist appearance and becomes dry and wrinkled (xerosis). Keratin debris and saprophytic bacteria (often Corynebacterium xerosis) accumulate over devitalized epithelium, producing the pathognomonic Bitot's spots.

If deficiency continues, the cornea itself dries, the stroma liquefies, and the eye undergoes keratomalacia, a rapid colliquative necrosis that can perforate the globe within 24 to 48 hours. This is why advanced xerophthalmia is a true ophthalmic emergency. The same epithelial dysfunction explains the increased susceptibility to measles, diarrhea, and respiratory infections, since vitamin A maintains mucosal barriers everywhere, not just in the eye.

A clinically important detail: measles depletes vitamin A stores acutely by reducing serum retinol and increasing urinary loss. A previously borderline child can crash into florid xerophthalmia within days of a measles episode. This bidirectional relationship (deficiency worsens measles, measles worsens deficiency) is heavily tested.

2. Clinical Manifestation and Classification (WHO Staging)

Code	Stage	Clinical Finding	Reversibility
XN	Night blindness	Difficulty seeing in dim light; child bumps into objects at dusk	Fully reversible
X1A	Conjunctival xerosis	Dry, dull, wrinkled bulbar conjunctiva	Fully reversible
X1B	Bitot's spots	Foamy triangular grayish-white plaques (Bitot's spots) on temporal bulbar conjunctiva	Reversible
X2	Corneal xerosis	Hazy, dry cornea with punctate keratopathy	Reversible with prompt treatment
X3A	Corneal ulceration / keratomalacia, less than one-third of cornea	Sharply demarcated ulcer or area of softening	Partial scarring expected
X3B	Corneal ulceration / keratomalacia, one-third or more of cornea	Extensive corneal melting, risk of perforation	Vision loss likely
XS	Corneal scar	Healed opacity from prior keratomalacia	Permanent
XF	Xerophthalmic fundus	Whitish peripheral retinal lesions	Reversible

The progression follows a predictable sequence: rod dysfunction first (XN), then conjunctiva (X1), then cornea (X2 to X3), and finally scarring (XS). On a vignette, the stage tells you the urgency. XN through X1B are outpatient problems; X2 onwards is an emergency.

3. Diagnostic Workup

Test	Purpose	Threshold / Finding
Serum retinol	Confirms biochemical deficiency	$< 20\ \mu g/dL$ (deficient); $< 10\ \mu g/dL$ (severe)
Dark adaptation test	Functional rod assessment	Delayed adaptation curve
Electroretinography	Detects subclinical rod dysfunction	Reduced scotopic b-wave amplitude
Conjunctival impression cytology	Documents goblet cell loss	Absence of goblet cells, presence of keratinized epithelium
Retinol-binding protein	Surrogate marker (cheaper)	Reduced
Therapeutic trial	Confirms diagnosis when labs unavailable	Resolution of night blindness within 48 hours of vitamin A dosing

In practice, xerophthalmia is a clinical diagnosis. A malnourished preschool child with night blindness and Bitot's spots needs vitamin A immediately. You do not wait for serum retinol to come back. Laboratory confirmation is for atypical presentations, malabsorption workups, or research settings.

For research-level confirmation, conjunctival impression cytology (showing loss of goblet cells and keratinized epithelium) is the histologic gold standard, and electroretinography is the functional gold standard for subclinical rod dysfunction. These rarely show up as test answers but worth recognizing.

A common vignette twist is the child with cystic fibrosis or biliary atresia presenting with night blondness or dry eyes. Here, the deficiency is from fat malabsorption, not poor intake, and the workup adds fecal elastase, sweat chloride, or cholestasis evaluation.

4. Management and Treatment

Population	Day 1 Dose	Day 2 Dose	Day 15 Dose
Infants under 6 months	50,000 IU orally	50,000 IU orally	50,000 IU orally
Infants 6 to 12 months	100,000 IU orally	100,000 IU orally	100,000 IU orally
Children over 12 months and adults	200,000 IU orally	200,000 IU orally	200,000 IU orally

The acute treatment of xerophthalmia rests on a three-dose oral regimen: a dose on day 1, repeated on day 2, and a third dose on day 15. The day 15 dose replenishes hepatic stores. Oil-based oral preparations are preferred. Intramuscular water-miscible vitamin A is reserved for children with severe vomiting, severe diarrhea, or malabsorption who cannot retain the oral dose.

Alongside vitamin A, manage the underlying cause. In protein-energy malnutrition, refeeding must accompany supplementation since retinol-binding protein synthesis requires adequate protein. In cystic fibrosis or cholestatic liver disease, give pancreatic enzyme replacement and use water-miscible vitamin A formulations that do not require bile salts for absorption. In recent measles, the WHO recommends two doses of vitamin A on consecutive days regardless of nutritional status because measles precipitates acute deficiency.

Corneal complications are an emergency. Keratomalacia (X3A or X3B) requires immediate vitamin A, topical antibiotics to prevent superinfection, atropine for cycloplegia, and a protective eye shield. Avoid topical steroids; they accelerate corneal melting. Patching is contraindicated in active ulceration. Ophthalmology consultation should not be delayed.

Pregnancy is the major contraindication trap. High-dose vitamin A (above 10,000 IU per day in early pregnancy) is teratogenic, causing craniofacial, cardiac, thymic, and central nervous system malformations. For pregnant or potentially pregnant women with mild xerophthalmia (night blindness or Bitot's spots only), use the low-dose regimen of 5,000 to 10,000 IU daily or 25,000 IU weekly. However, when corneal disease threatens vision, the full sight-saving dose is given because blindness in the mother outweighs theoretical fetal risk.

The next best step logic to memorize:

Night blindness in a malnourished child, no eye findings yet: oral vitamin A immediately, do not wait for labs.
Bitot's spots present: oral vitamin A immediately plus dietary counseling.
Corneal involvement: oral vitamin A plus topical antibiotic plus eye shield plus urgent ophthalmology referral.
Recent measles in a child from an endemic area: prophylactic vitamin A on two consecutive days regardless of eye findings.
Pregnant patient with night blindness: low-dose daily or weekly regimen, never the high-dose pulse.

5. Prophylaxis and Public Health Prevention

Target Group	Capsule Color	Dose	Schedule	Frequency
Infants 6 to 11 months	Blue (kapsul biru)	100,000 IU	February or August	Once per year
Children 12 to 59 months	Red (kapsul merah)	200,000 IU	February and August	Twice per year
Postpartum mothers (ibu nifas, 0 to 42 days)	Red (kapsul merah)	200,000 IU	Dose 1: immediately after delivery Dose 2: 24 hours after the first dose	Two doses total per delivery

Indonesia runs one of the longest-standing universal vitamin A supplementation programs in the world. The program operates through Posyandu, Puskesmas, Pustu, Poskesdes, and partner facilities, and the capsules are distributed free of charge.

The two designated months are February (Februari) and August (Agustus), chosen so that supplementation occurs roughly every six months and aligns with hepatic storage capacity. Vitamin A is fat-soluble and stored in the liver, so a single high-dose pulse can cover the body's needs for approximately four to six months without requiring daily dosing.

Two capsule preparations are used:

The blue capsule (kapsul biru) contains 100,000 IU of retinol palmitate or acetate and is given to infants aged 6 to 11 months. Infants in this age band receive the capsule once a year, either in February or in August, depending on when they cross the six-month threshold. Vitamin A supplementation is not started before six months of age because exclusive breastfeeding is the recommended source until then, and breast milk from a well-nourished mother provides adequate vitamin A.
The red capsule (kapsul merah) contains 200,000 IU and is given to children aged 12 to 59 months twice a year, once in February and once in August. The same red capsule is used for postpartum mothers.

The administration technique is straightforward: snip the nipple of the soft capsule with clean scissors, squeeze the contents directly into the child's mouth, and ensure the entire dose is swallowed.

Postpartum mothers up to 42 days after delivery receive two doses of the red 200,000 IU capsule. The first dose is given immediately after delivery, and the second dose is given at least 24 hours after the first dose. The rationale rests on breast milk pharmacology: a single 200,000 IU dose raises breast milk vitamin A content for approximately 60 days, while the two-dose regimen extends adequate breast milk vitamin A content through the first six months of the infant's life, covering the period of exclusive breastfeeding. This is the strategy by which Indonesia protects infants under six months from deficiency without giving the infant any direct supplementation.

If a mother misses the immediate postpartum dose, she can still receive the capsule any time within the 42-day puerperium window. After day 42, she is no longer eligible.

6. Differential Diagnosis and Distractors

Differential Diagnosis	Why It Is Similar	Key Discriminator
Sjögren syndrome	Both present with dry eyes and gritty sensation	Sjögren occurs in middle-aged women with dry mouth, positive anti-Ro/anti-La antibodies, and no night blindness; xerophthalmia features nyctalopia and Bitot's spots
Retinitis pigmentosa	Both cause night blindness	Retinitis pigmentosa shows bone-spicule pigmentation on fundoscopy, peripheral visual field constriction, and family history; vitamin A levels are normal
Allergic conjunctivitis with xerosis	Both can show conjunctival changes	Allergic disease has itching, papillae, and seasonal pattern; no Bitot's spots, no night blindness
Stevens-Johnson syndrome sequelae	Causes severe ocular surface dryness and goblet cell loss	History of drug reaction with mucocutaneous involvement; symblepharon present
Trachoma	Endemic in similar populations, causes corneal scarring	Trachoma shows tarsal follicles, Herbert's pits, and trichiasis; caused by Chlamydia trachomatis, not nutritional
Vitamin B2 (riboflavin) deficiency	Can cause photophobia and corneal vascularization	Riboflavin deficiency features angular cheilitis, glossitis, and seborrheic dermatitis; no night blindness or Bitot's spots
Congenital stationary night blindness	Lifelong night blindness	Present from birth, no nutritional history, normal serum retinol, often X-linked
Measles keratoconjunctivitis (without deficiency)	Both can occur in the same child	Pure measles eye disease resolves with the rash; persistent corneal changes after the acute illness signal underlying vitamin A deficiency

The two highest-yield distractors are retinitis pigmentosa (chosen when the test-taker latches onto night blindness in isolation) and Sjögren syndrome (chosen when the test-taker latches onto dry eyes). The discriminators are nutritional context, age group, and the presence of Bitot's spots.

7. Traps and High-Yield Pearls

The single most common error on questions about xerophthalmia is stopping at the first symptom and missing the staging. A child with night blindness alone has reversible disease and needs vitamin A; a child with corneal melting needs vitamin A plus topical antibiotics plus an eye shield plus emergency referral. The vignette will almost always describe physical findings precisely so that you can place the patient on the WHO staging ladder, and the right management answer depends on which rung the patient is on.

The second classic trap is the pregnant patient. Test writers love to set up a malnourished pregnant woman with night blindness and offer a 200,000 IU pulse dose as a tempting answer. This is wrong because of teratogenicity. The correct approach in mild disease during pregnancy is daily low-dose supplementation (5,000 to 10,000 IU per day) or weekly dosing (25,000 IU per week). The 200,000 IU pulse is reserved for sight-threatening corneal disease where the maternal benefit outweighs fetal risk.

The third trap is the post-measles child. A vignette describing a preschool child from a low-resource setting who developed eye complaints "two weeks after recovering from a febrile rash" is testing whether you recognize that measles unmasks subclinical vitamin A deficiency. The answer is vitamin A on two consecutive days, even before any laboratory confirmation.

The fourth trap is the fat malabsorption presentation. A teenager with cystic fibrosis or a child with biliary atresia presenting with dry eyes and night blindness is testing whether you understand that vitamin A is fat-soluble. Oral oil-based preparations will not work; you need water-miscible vitamin A and treatment of the underlying malabsorption. Other fat-soluble vitamin deficiencies (D, E, K) often coexist and may be tested in the same vignette.

The fifth and most subtle trap is mistaking Bitot's spots for pinguecula or pterygium. Pinguecula and pterygium are degenerative changes in adults from sun exposure; Bitot's spots are foamy keratinized patches in malnourished children. The age and nutritional context decide.

The core competency being tested is recognition of a clinical syndrome that combines a nutritional history, a pathognomonic eye finding, and a staged emergency response. Test writers reward candidates who can move quickly from "malnourished child with night blindness" to "give oral vitamin A now" without waiting for serum retinol, and who can adjust the dose for pregnancy and the route for malabsorption. Master the staging table, the dosing schedule, and the pregnancy exception, and questions on this topic become free points.

1e:["$","$L2d",null,{"article":{"id":"a293cbee-c07d-42b5-b760-cf034178ea33","title":"Xeroftalmia","content":"$2e","category":"Oftalmologi","created_at":"2026-04-29T03:31:05.043109+00:00","status":"published","subcategory":null},"questionCount":7,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-clinical-manifestation-and-classification-who-staging","num":"02","title":"Clinical Manifestation and Classification (WHO Staging)"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-prophylaxis-and-public-health-prevention","num":"05","title":"Prophylaxis and Public Health Prevention"},{"id":"section-differential-diagnosis-and-distractors","num":"06","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"07","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]